Longevity
Two large heart drug trials failed despite genetic logic backing them
By Life and Health Today Staff, . Life and Health Today.
Two large cardiovascular drug trials presented Saturday at the annual meeting of the American Heart Association came back negative, and the reasons why matter to anyone following the argument that new science, whether genetic, computational or otherwise, can reliably shorten the path from idea to medicine.
What the trials tested
The first involved pelacarsen, a drug made by Novartis, designed to lower a substance in the blood called lp(a), short for lipoprotein(a), a fatty particle that genetics research had identified as a driver of cardiovascular risk. The logic was straightforward: if elevated lp(a) raises the odds of a heart attack or stroke, and if pelacarsen reliably lowers lp(a), then the drug should reduce those events. According to STAT News, which covered the meeting, pelacarsen did lower lp(a) as expected. It did not reduce the rate of heart attacks and strokes.
The second trial, run by Novo Nordisk, tested an anti-inflammatory drug aimed at a protein called IL-6, interleukin-6, a signaling molecule involved in the body's inflammatory response. Inflammation has long been suspected as a contributor to cardiovascular disease, and IL-6 was a plausible target. The trial also showed no benefit, the publication reported.
Why genetics pointed the wrong way
Both programs were built on what researchers call genetic validation, the idea that if a gene variant associated with lower levels of a substance also correlates with lower disease rates in large population studies, then a drug that mimics that effect should work. It is a more rigorous starting point than earlier drug development approaches, and it was supposed to improve the odds that a compound would succeed in a clinical trial.
These two trials suggest that the logic, while sound in principle, does not guarantee a result. Lowering a marker in the blood is not the same as preventing the disease the marker is associated with. That distinction, between a surrogate marker and an actual clinical outcome, is one of the most consequential in medicine, and these trials are a fresh illustration of why regulators and researchers treat it seriously.
The broader pattern
STAT News framed the failures as part of a recurring pattern in cardiovascular research, where technologies expected to accelerate drug development have repeatedly fallen short. The publication drew an explicit parallel to current enthusiasm around artificial intelligence in drug discovery, noting that the heart disease field has seen this cycle before with other promising tools.
That parallel is worth sitting with. The argument for AI in drug development often rests on the same foundation as the argument for genetic validation: better target selection should mean fewer late-stage failures. The cardiovascular record suggests that better selection raises the floor without removing the ceiling on failure.
What this does not settle
Neither trial result means that lp(a) or IL-6 are irrelevant to heart disease, or that drugs targeting them cannot work. A different drug, a different patient population, or a different trial design might produce a different answer. What the results do establish is that two large, well-resourced programs built on credible biological reasoning did not deliver clinical benefit in the populations tested.
For anyone weighing a treatment or following a biomarker on a blood panel, the practical point is this: a marker moving in the right direction on a lab report is not the same as a reduced risk of a heart attack. That question, whether moving the marker actually changes outcomes, is what a clinical trial is designed to answer, and these two answered it in the negative.
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.